Channel Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

Company Data

Name Chromocell Therapeutics Corporation Common Stock

Company Channel Therapeutics Corporation

Symbol CHRO

Website https://channeltherapeutics.com

Primary Exchange

NYSE

ISIN US1711261057

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Francis Knuettel II,

Country United States of America

Currency USD

Employees 0,0 T

Address 4400 Route 9 South, 07728 Freehold

IPO Date 2024-02-16

Stock Splits

Date	Split
02.07.2025	1:10

ID Changes

Date	From	To
02.07.2025	CHRO	PTHS

Ticker Symbols

Name	Symbol
NYSE	CHRO
NYSE	PTHS

More Shares

Investors who hold Chromocell Therapeutics Corporation Common Stock also have the following shares in their portfolio:

EUR/SGD SINGAPUR-DOLLAR Currency

TOA Paint (Thailand) Public Company Limited Share

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog